$BCRX
BIOCRYST PHARMACEUTICALS INC Stock $bcrx

$bcrx Overview Financials Valuation SEC Filings Company Website

2017 Q3 Form 10-Q Financial Statement

#000117184317006746 Filed on November 08, 2017

Income Statement

Concept	2017 Q3	2016 Q3
Revenue	$8.760M	$7.763M
YoY Change	12.84%	-29.34%
Cost Of Revenue	$1.142M
YoY Change
Gross Profit	$7.618M	$7.763M
YoY Change	-1.87%	-19.48%
Gross Profit Margin	86.96%	100.0%
Selling, General & Admin	$3.343M	$2.756M
YoY Change	21.3%	0.92%
% of Gross Profit	43.88%	35.5%
Research & Development	$17.51M	$14.11M
YoY Change	24.13%	-29.71%
% of Gross Profit	229.84%	181.7%
Depreciation & Amortization	$180.0K	$170.0K
YoY Change	5.88%	240.0%
% of Gross Profit	2.36%	2.19%
Operating Expenses	$20.85M	$16.86M
YoY Change	23.67%	-26.04%
Operating Profit	-$13.35M	-$9.241M
YoY Change	44.45%	-29.79%
Interest Expense	$2.140M	$1.465M
YoY Change	46.08%	18.05%
% of Operating Profit
Other Income/Expense, Net
YoY Change
Pretax Income	-$15.13M	-$11.53M
YoY Change	31.22%	-21.14%
Income Tax
% Of Pretax Income
Net Earnings	-$15.13M	-$11.53M
YoY Change	31.28%	-21.15%
Net Earnings / Revenue	-172.76%	-148.5%
Basic Earnings Per Share
Diluted Earnings Per Share	-$181.0K	-$156.4K
COMMON SHARES
Basic Shares Outstanding
Diluted Shares Outstanding	83.57M	73.73M

Balance Sheet

Concept	2017 Q3	2016 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments	$161.6M	$52.82M
YoY Change	205.98%	-24.89%
Cash & Equivalents	$117.8M	$35.39M
Short-Term Investments	$43.85M	$17.43M
Other Short-Term Assets	$4.700M	$3.600M
YoY Change	30.56%	-49.3%
Inventory		$2.232M
Prepaid Expenses
Receivables	$8.985M	$5.968M
Other Receivables	$0.00	$0.00
Total Short-Term Assets	$175.4M	$64.63M
YoY Change	171.34%	-23.51%
LONG-TERM ASSETS
Property, Plant & Equipment	$9.613M	$10.10M
YoY Change	-4.77%	780.89%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments	$4.500M	$14.40M
YoY Change	-68.75%	-60.11%
Other Assets	$1.955M	$2.190M
YoY Change	-10.73%	-58.2%
Total Long-Term Assets	$16.12M	$26.87M
YoY Change	-40.0%	-50.66%
TOTAL ASSETS
Total Short-Term Assets	$175.4M	$64.63M
Total Long-Term Assets	$16.12M	$26.87M
Total Assets	$191.5M	$91.50M
YoY Change	109.28%	-34.15%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$4.603M	$2.760M
YoY Change	66.78%	-27.02%
Accrued Expenses	$11.87M	$10.78M
YoY Change	10.1%	-53.18%
Deferred Revenue
YoY Change
Short-Term Debt	$28.60M	$28.10M
YoY Change	1.78%	-6.33%
Long-Term Debt Due	$4.800M
YoY Change
Total Short-Term Liabilities	$69.24M	$51.52M
YoY Change	34.39%	-20.05%
LONG-TERM LIABILITIES
Long-Term Debt	$21.10M	$25.30M
YoY Change	-16.6%
Other Long-Term Liabilities	$500.0K	$10.60M
YoY Change	-95.28%	2.91%
Total Long-Term Liabilities	$21.60M	$35.90M
YoY Change	-39.83%	248.54%
TOTAL LIABILITIES
Total Short-Term Liabilities	$69.24M	$51.52M
Total Long-Term Liabilities	$21.60M	$35.90M
Total Liabilities	$90.90M	$87.50M
YoY Change	3.89%	18.08%
SHAREHOLDERS EQUITY
Retained Earnings	-$612.3M	-$561.6M
YoY Change	9.04%	13.96%
Common Stock	$984.0K	$738.0K
YoY Change	33.33%	0.68%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$100.6M	$3.993M
YoY Change
Total Liabilities & Shareholders Equity	$191.5M	$91.50M
YoY Change	109.28%	-34.15%

Cashflow Statement

Concept	2017 Q3	2016 Q3
OPERATING ACTIVITIES
Net Income	-$15.13M	-$11.53M
YoY Change	31.28%	-21.15%
Depreciation, Depletion And Amortization	$180.0K	$170.0K
YoY Change	5.88%	240.0%
Cash From Operating Activities	-$12.43M	-$17.55M
YoY Change	-29.17%	38.63%
INVESTING ACTIVITIES
Capital Expenditures	-$190.0K	-$180.0K
YoY Change	5.56%	20.0%
Acquisitions
YoY Change
Other Investing Activities	$4.390M	$22.13M
YoY Change	-80.16%	-222.94%
Cash From Investing Activities	$4.200M	$21.95M
YoY Change	-80.87%	-221.0%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net	$86.25M
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	86.31M	22.33M
YoY Change	286.52%	3389.06%
NET CHANGE
Cash From Operating Activities	-12.43M	-17.55M
Cash From Investing Activities	4.200M	21.95M
Cash From Financing Activities	86.31M	22.33M
Net Change In Cash	78.08M	26.73M
YoY Change	192.11%	-188.63%
FREE CASH FLOW
Cash From Operating Activities	-$12.43M	-$17.55M
Capital Expenditures	-$190.0K	-$180.0K
Free Cash Flow	-$12.24M	-$17.37M
YoY Change	-29.53%	38.85%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value
CY2017Q3	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-15136000
	bcrx	Amortization Of Discount And Premium On Investments AmortizationOfDiscountAndPremiumOnInvestments	125000
	bcrx	Amortization Of Discount And Premium On Investments AmortizationOfDiscountAndPremiumOnInvestments	499000
CY2017Q3	bcrx	Available For Sale Securities Accrued Interest AvailableForSaleSecuritiesAccruedInterest	169000
CY2016Q4	bcrx	Available For Sale Securities Accrued Interest AvailableForSaleSecuritiesAccruedInterest	77000
CY2017Q3	bcrx	Available For Sale Securities Debt Maturities After One Through Two Years Fair Value AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughTwoYearsFairValue	4539000
CY2016Q4	bcrx	Available For Sale Securities Debt Maturities After One Through Two Years Fair Value AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughTwoYearsFairValue	8926000
CY2017Q3	bcrx	Collaborative And Other Research And Development CollaborativeAndOtherResearchAndDevelopment	6817000
CY2016Q3	bcrx	Collaborative And Other Research And Development CollaborativeAndOtherResearchAndDevelopment	4262000
	bcrx	Collaborative And Other Research And Development CollaborativeAndOtherResearchAndDevelopment	12543000
	bcrx	Collaborative And Other Research And Development CollaborativeAndOtherResearchAndDevelopment	11350000
CY2017Q3	bcrx	Collaborative And Other Research And Development Revenues CollaborativeAndOtherResearchAndDevelopmentRevenues	6817000
CY2016Q3	bcrx	Collaborative And Other Research And Development Revenues CollaborativeAndOtherResearchAndDevelopmentRevenues	4262000
	bcrx	Collaborative And Other Research And Development Revenues CollaborativeAndOtherResearchAndDevelopmentRevenues	12543000
	bcrx	Collaborative And Other Research And Development Revenues CollaborativeAndOtherResearchAndDevelopmentRevenues	11350000
CY2017Q3	bcrx	Deferred Collaboration Expense Assets DeferredCollaborationExpenseAssets	15000
CY2016Q4	bcrx	Deferred Collaboration Expense Assets DeferredCollaborationExpenseAssets	199000
	bcrx	Deferred Collaboration Expense Changes In Operating Assets And Liabilities DeferredCollaborationExpenseChangesInOperatingAssetsAndLiabilities	-51000
	bcrx	Deferred Collaboration Expense Changes In Operating Assets And Liabilities DeferredCollaborationExpenseChangesInOperatingAssetsAndLiabilities	-43000
CY2017Q3	bcrx	Employee Service Share Based Compensation Nonvested Awards Compensation Cost Expected To Be Recognized For Remainder Of Fiscal Year EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedForRemainderOfFiscalYear	2264000
CY2017Q3	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	711965000
CY2016Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	566913000
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	10307000
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	6478000
CY2017Q3	us-gaap	Amortization Of Financing Costs AmortizationOfFinancingCosts	219000
CY2017Q3	bcrx	Employee Service Share Based Compensation Nonvested Awards Compensation Cost Expected To Be Recognized Year Five EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedYearFive	351000
CY2017Q3	bcrx	Employee Service Share Based Compensation Nonvested Awards Compensation Cost Expected To Be Recognized Year Four EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedYearFour	2395000
CY2017Q3	bcrx	Employee Service Share Based Compensation Nonvested Awards Compensation Cost Expected To Be Recognized Year Three EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedYearThree	4527000
CY2017Q3	bcrx	Employee Service Share Based Compensation Nonvested Awards Compensation Cost Expected To Be Recognized Year Two EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedYearTwo	6745000
	bcrx	Increase Decrease In Financing Lease Obligations IncreaseDecreaseInFinancingLeaseObligations	139000
	bcrx	Increase Decrease In Financing Lease Obligations IncreaseDecreaseInFinancingLeaseObligations	300000
CY2017Q3	bcrx	Lease Financing Obligation Net Of Current LeaseFinancingObligationNetOfCurrent	2770000
CY2016Q4	bcrx	Lease Financing Obligation Net Of Current LeaseFinancingObligationNetOfCurrent	2704000
CY2015Q1	bcrx	Maximum Aggregate Offering Price MaximumAggregateOfferingPrice	150000000
	bcrx	Number Of Stockbased Compensation Plans NumberOfStockbasedCompensationPlans	2
CY2017Q3	us-gaap	Accounts Payable Current AccountsPayableCurrent	4603000
CY2016Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	4269000
CY2017Q3	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	8985000
CY2016Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	8768000
CY2017Q3	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	11871000
CY2016Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	10836000
CY2017Q3	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-17000
CY2016Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-12000
CY2016Q3	us-gaap	Amortization Of Financing Costs AmortizationOfFinancingCosts	116000
	us-gaap	Amortization Of Financing Costs AmortizationOfFinancingCosts	658000
	us-gaap	Amortization Of Financing Costs AmortizationOfFinancingCosts	335000
CY2017Q3	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	1996000
CY2016Q3	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	1291000
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	2519000
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	1190000
CY2017Q3	us-gaap	Assets Assets	191492000
CY2016Q4	us-gaap	Assets Assets	89847000
CY2017Q3	us-gaap	Assets Current AssetsCurrent	175370000
CY2016Q4	us-gaap	Assets Current AssetsCurrent	66987000
CY2017Q3	us-gaap	Available For Sale Securities AvailableForSaleSecurities	48387000
CY2016Q4	us-gaap	Available For Sale Securities AvailableForSaleSecurities	41472000
CY2017Q3	us-gaap	Available For Sale Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	4000
CY2017Q3	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	200000000
CY2016Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	200000000
CY2017Q3	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	98389000
CY2016Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	73782000
CY2017Q3	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	98389000
CY2016Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	73782000
CY2017Q3	us-gaap	Common Stock Value CommonStockValue	984000
CY2016Q4	us-gaap	Common Stock Value CommonStockValue	738000
CY2016Q4	us-gaap	Available For Sale Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	11000
CY2017Q3	us-gaap	Available For Sale Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	21000
CY2016Q4	us-gaap	Available For Sale Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	23000
CY2017Q3	us-gaap	Available For Sale Securities Amortized Cost AvailableForSaleSecuritiesAmortizedCost	48235000
CY2016Q4	us-gaap	Available For Sale Securities Amortized Cost AvailableForSaleSecuritiesAmortizedCost	41407000
CY2017Q3	us-gaap	Available For Sale Securities Debt Maturities Within One Year Fair Value AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue	43848000
CY2016Q4	us-gaap	Available For Sale Securities Debt Maturities Within One Year Fair Value AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue	32546000
CY2017Q3	us-gaap	Available For Sale Securities Debt Securities Current AvailableForSaleSecuritiesDebtSecuritiesCurrent	43848000
CY2016Q4	us-gaap	Available For Sale Securities Debt Securities Current AvailableForSaleSecuritiesDebtSecuritiesCurrent	32546000
CY2017Q3	us-gaap	Available For Sale Securities Debt Securities Noncurrent AvailableForSaleSecuritiesDebtSecuritiesNoncurrent	4539000
CY2016Q4	us-gaap	Available For Sale Securities Debt Securities Noncurrent AvailableForSaleSecuritiesDebtSecuritiesNoncurrent	8926000
CY2017Q3	us-gaap	Capital Lease Obligations Current CapitalLeaseObligationsCurrent	73000
CY2016Q4	us-gaap	Capital Lease Obligations Current CapitalLeaseObligationsCurrent
CY2017Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	117776000
CY2016Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	22104000
CY2015Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	28899000
CY2016Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	35387000
	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	95672000
	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	6488000
CY2017Q3	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.01
CY2016Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.01
CY2016Q3	us-gaap	Costs And Expenses CostsAndExpenses	17004000
	us-gaap	Costs And Expenses CostsAndExpenses	60846000
	us-gaap	Costs And Expenses CostsAndExpenses	57789000
CY2016Q3	us-gaap	Cost Of Goods Sold CostOfGoodsSold
	us-gaap	Cost Of Goods Sold CostOfGoodsSold	1142000
	us-gaap	Cost Of Goods Sold CostOfGoodsSold
CY2017Q3	us-gaap	Costs And Expenses CostsAndExpenses	22109000
CY2016Q3	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-11552000
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-46244000
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-50413000
CY2017Q3	us-gaap	Cost Of Goods Sold CostOfGoodsSold	1142000
CY2017Q3	us-gaap	Deferred Costs Current DeferredCostsCurrent	218000
CY2016Q4	us-gaap	Deferred Costs Current DeferredCostsCurrent	85000
CY2017Q3	us-gaap	Deferred Rent Credit Noncurrent DeferredRentCreditNoncurrent	178000
CY2016Q4	us-gaap	Deferred Rent Credit Noncurrent DeferredRentCreditNoncurrent	244000
CY2017Q3	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	8686000
CY2016Q4	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	2022000
CY2017Q3	us-gaap	Deferred Revenue Noncurrent DeferredRevenueNoncurrent	296000
CY2016Q4	us-gaap	Deferred Revenue Noncurrent DeferredRevenueNoncurrent	8184000
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	522000
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	311000
CY2017Q3	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.18
CY2016Q3	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.16
	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.58
	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.69
	us-gaap	Gain Loss On Disposition Of Assets1 GainLossOnDispositionOfAssets1
	us-gaap	Gain Loss On Disposition Of Assets1 GainLossOnDispositionOfAssets1	-21000
CY2017Q3	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized	16282000
	us-gaap	Gain Loss On Foreign Currency Derivative Instruments Not Designated As Hedging Instruments GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments	-6561000
CY2017Q3	us-gaap	Gain Loss On Foreign Currency Derivative Instruments Not Designated As Hedging Instruments GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments	130000
CY2016Q3	us-gaap	Gain Loss On Foreign Currency Derivative Instruments Not Designated As Hedging Instruments GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments	-931000
	us-gaap	Gain Loss On Foreign Currency Derivative Instruments Not Designated As Hedging Instruments GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments	-892000
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	1303000
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-12066000
	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	-1224000
	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	-1075000
	us-gaap	Increase Decrease In Derivative Assets IncreaseDecreaseInDerivativeAssets	-1858000
	us-gaap	Increase Decrease In Derivative Assets IncreaseDecreaseInDerivativeAssets	-7372000
	us-gaap	Increase Decrease In Interest Payable Net IncreaseDecreaseInInterestPayableNet	1715000
	us-gaap	Increase Decrease In Interest Payable Net IncreaseDecreaseInInterestPayableNet	817000
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	-500000
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	620000
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-17000
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-667000
	us-gaap	Increase Decrease In Receivables IncreaseDecreaseInReceivables	217000
	us-gaap	Increase Decrease In Receivables IncreaseDecreaseInReceivables	-275000
	us-gaap	Increase Decrease In Restricted Cash IncreaseDecreaseInRestrictedCash	1576000
	us-gaap	Increase Decrease In Restricted Cash IncreaseDecreaseInRestrictedCash	-106000
CY2017Q3	us-gaap	Interest And Other Income InterestAndOtherIncome	225000
CY2016Q3	us-gaap	Interest And Other Income InterestAndOtherIncome	109000
	us-gaap	Interest And Other Income InterestAndOtherIncome	537000
	us-gaap	Interest And Other Income InterestAndOtherIncome	695000
CY2017Q3	us-gaap	Interest Expense InterestExpense	2140000
CY2016Q3	us-gaap	Interest Expense InterestExpense	1465000
	us-gaap	Interest Expense InterestExpense	6334000
	us-gaap	Interest Expense InterestExpense	4356000
CY2017Q3	us-gaap	Interest Expense Debt InterestExpenseDebt	2140000
CY2016Q3	us-gaap	Interest Expense Debt InterestExpenseDebt	1465000
	us-gaap	Interest Expense Debt InterestExpenseDebt	6334000
	us-gaap	Interest Expense Debt InterestExpenseDebt	4356000
CY2017Q3	us-gaap	Interest Payable Current InterestPayableCurrent	10705000
CY2016Q4	us-gaap	Interest Payable Current InterestPayableCurrent	8990000
CY2017Q3	us-gaap	Inventory Net InventoryNet
CY2016Q4	us-gaap	Inventory Net InventoryNet	500000
CY2017Q3	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	191492000
CY2016Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	89847000
CY2017Q3	us-gaap	Liabilities Current LiabilitiesCurrent	69237000
CY2016Q4	us-gaap	Liabilities Current LiabilitiesCurrent	54360000
CY2017Q3	us-gaap	Line Of Credit LineOfCredit	18379000
CY2016Q4	us-gaap	Line Of Credit LineOfCredit	22777000
CY2017Q3	us-gaap	Lines Of Credit Current LinesOfCreditCurrent	4727000
CY2016Q4	us-gaap	Lines Of Credit Current LinesOfCreditCurrent
CY2017Q3	us-gaap	Long Term Debt LongTermDebt	23000000
CY2017Q3	us-gaap	Long Term Debt Maturities Repayments Of Principal In Year Five LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive	2300000
CY2017Q3	us-gaap	Long Term Debt Maturities Repayments Of Principal In Year Four LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour	6900000
CY2017Q3	us-gaap	Long Term Debt Maturities Repayments Of Principal In Year Three LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree	6900000
CY2017Q3	us-gaap	Long Term Debt Maturities Repayments Of Principal In Year Two LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo	6900000
CY2017Q3	us-gaap	Long Term Debt Maturities Repayments Of Principal Remainder Of Fiscal Year LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear
	us-gaap	Loss On Sale Of Investments LossOnSaleOfInvestments	0
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	135130000
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	20972000
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-8834000
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	33100000
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-30624000
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-47584000
	us-gaap	Net Income Loss NetIncomeLoss	-46239000
	us-gaap	Net Income Loss NetIncomeLoss	-50641000
CY2017Q3	us-gaap	Net Income Loss NetIncomeLoss	-15134000
CY2016Q3	us-gaap	Net Income Loss NetIncomeLoss	-11528000
CY2017Q3	us-gaap	Notes Payable Current NotesPayableCurrent	28572000
CY2016Q4	us-gaap	Notes Payable Current NotesPayableCurrent	28243000
CY2017Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-13349000
CY2016Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-9241000
	us-gaap	Operating Income Loss OperatingIncomeLoss	-39550000
	us-gaap	Operating Income Loss OperatingIncomeLoss	-40419000
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock
	us-gaap	Proceeds From Lines Of Credit ProceedsFromLinesOfCredit
	us-gaap	Proceeds From Lines Of Credit ProceedsFromLinesOfCredit	22658000
CY2017Q3	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	1955000
CY2016Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	3813000
CY2017Q3	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	-2000
CY2016Q3	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	-24000
	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	-5000
	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	228000
	us-gaap	Payments For Hedge Financing Activities PaymentsForHedgeFinancingActivities
	us-gaap	Payments For Hedge Financing Activities PaymentsForHedgeFinancingActivities	2190000
	us-gaap	Payments To Acquire Available For Sale Securities Debt PaymentsToAcquireAvailableForSaleSecuritiesDebt	39572000
	us-gaap	Payments To Acquire Available For Sale Securities Debt PaymentsToAcquireAvailableForSaleSecuritiesDebt
	us-gaap	Payments To Acquire Productive Assets PaymentsToAcquireProductiveAssets	213000
	us-gaap	Payments To Acquire Productive Assets PaymentsToAcquireProductiveAssets	5278000
CY2017Q3	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2016Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2017Q3	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	5000000
CY2016Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	5000000
CY2017Q3	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0
CY2016Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0
CY2017Q3	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0
CY2016Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0
CY2017Q3	us-gaap	Preferred Stock Value PreferredStockValue	0
CY2016Q4	us-gaap	Preferred Stock Value PreferredStockValue	0
CY2017Q3	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	1421000
CY2016Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	1438000
CY2017Q1	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	47750000
CY2017Q3	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	85750000
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	133500000
	us-gaap	Proceeds From Sale And Maturity Of Available For Sale Securities ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities	32527000
	us-gaap	Proceeds From Sale And Maturity Of Available For Sale Securities ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities	38272000
	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	1491000
	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	204000
CY2017Q3	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	9613000
CY2016Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	9922000
CY2017Q3	us-gaap	Receivables Net Current ReceivablesNetCurrent	8985000
CY2016Q4	us-gaap	Receivables Net Current ReceivablesNetCurrent	8768000
	us-gaap	Reclassification From Accumulated Other Comprehensive Income Current Period Before Tax ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodBeforeTax	0
	us-gaap	Reclassification From Accumulated Other Comprehensive Income Current Period Before Tax ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodBeforeTax	11000
CY2017Q3	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	17509000
CY2016Q3	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	14105000
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	50038000
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	48850000
CY2017Q3	us-gaap	Restricted Cash And Cash Equivalents At Carrying Value RestrictedCashAndCashEquivalentsAtCarryingValue	3122000
CY2016Q4	us-gaap	Restricted Cash And Cash Equivalents At Carrying Value RestrictedCashAndCashEquivalentsAtCarryingValue	1546000
CY2017Q3	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-612300000
CY2016Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-566061000
CY2017Q3	us-gaap	Revenues Revenues	8760000
CY2016Q3	us-gaap	Revenues Revenues	7763000
	us-gaap	Revenues Revenues	21296000
	us-gaap	Revenues Revenues	17370000
CY2017Q3	us-gaap	Royalty Expense RoyaltyExpense	115000
CY2016Q3	us-gaap	Royalty Expense RoyaltyExpense	143000
	us-gaap	Royalty Expense RoyaltyExpense	431000
	us-gaap	Royalty Expense RoyaltyExpense	247000
CY2017Q3	us-gaap	Royalty Revenue RoyaltyRevenue	442000
CY2016Q3	us-gaap	Royalty Revenue RoyaltyRevenue	3501000
	us-gaap	Royalty Revenue RoyaltyRevenue	7252000
	us-gaap	Royalty Revenue RoyaltyRevenue	6020000
CY2017Q3	us-gaap	Sales Revenue Goods Net SalesRevenueGoodsNet	1501000
CY2016Q3	us-gaap	Sales Revenue Goods Net SalesRevenueGoodsNet
	us-gaap	Sales Revenue Goods Net SalesRevenueGoodsNet	1501000
	us-gaap	Sales Revenue Goods Net SalesRevenueGoodsNet
CY2017Q3	us-gaap	Sales Revenue Net SalesRevenueNet	8760000
CY2016Q3	us-gaap	Sales Revenue Net SalesRevenueNet	7763000
	us-gaap	Sales Revenue Net SalesRevenueNet	21296000
	us-gaap	Sales Revenue Net SalesRevenueNet	17370000
CY2017Q3	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	3343000
CY2016Q3	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	2756000
	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	9235000
	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	8692000
	us-gaap	Share Based Compensation ShareBasedCompensation	6478000
	us-gaap	Share Based Compensation ShareBasedCompensation	10307000
CY2017Q1	us-gaap	Shares Issued Price Per Share SharesIssuedPricePerShare	8.50
CY2017Q3	us-gaap	Shares Issued Price Per Share SharesIssuedPricePerShare	5.15
CY2017Q1	us-gaap	Stock Issued During Period Shares New Issues StockIssuedDuringPeriodSharesNewIssues	6061000
CY2017Q3	us-gaap	Stock Issued During Period Shares New Issues StockIssuedDuringPeriodSharesNewIssues	17864000
CY2017Q3	us-gaap	Stockholders Equity StockholdersEquity	100632000
CY2016Q4	us-gaap	Stockholders Equity StockholdersEquity	1578000
	us-gaap	Use Of Estimates UseOfEstimates	<div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style=" font-size: 10pt; margin: 0pt 0"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic;">Use of Estimates</div></div></div> <div style=" font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0"> </div> <div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0">The preparation of financial statements in conformity with U.S. GAAP requires the Company to make estimates and assumptions that affect the amounts reported in the financial statements. Actual results could differ from those estimates.</div></div></div></div></div>
CY2017Q3	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	83570000
CY2016Q3	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	73734000
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	79749000
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	73677000

Files In Submission

Name	View Source	Status
0001171843-17-006746-index-headers.html	Edgar Link	pending
0001171843-17-006746-index.html	Edgar Link	pending
0001171843-17-006746.txt	Edgar Link	pending
0001171843-17-006746-xbrl.zip	Edgar Link	pending
bcrx-20170930.xml	Edgar Link	completed
bcrx-20170930.xsd	Edgar Link	pending
bcrx-20170930_cal.xml	Edgar Link	unprocessable
bcrx-20170930_def.xml	Edgar Link	unprocessable
bcrx-20170930_lab.xml	Edgar Link	unprocessable
bcrx-20170930_pre.xml	Edgar Link	unprocessable
exh101_01.jpg	Edgar Link	pending
exh101_02.jpg	Edgar Link	pending
exh_101.htm	Edgar Link	pending
exh_311.htm	Edgar Link	pending
exh_312.htm	Edgar Link	pending
exh_321.htm	Edgar Link	pending
exh_322.htm	Edgar Link	pending
f10q_110817p.htm	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$BCRX
BIOCRYST PHARMACEUTICALS INC Stock $bcrx

2017 Q3 Form 10-Q Financial Statement

#000117184317006746 Filed on November 08, 2017

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$BCRX BIOCRYST PHARMACEUTICALS INC Stock $bcrx

2017 Q3 Form 10-Q Financial Statement

#000117184317006746 Filed on November 08, 2017

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$BCRX
BIOCRYST PHARMACEUTICALS INC Stock $bcrx